For the quarter ending 2026-03-31, CDIOW had $1,966,391 increase in cash & cash equivalents over the period. -$1,563,972 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,788,158 | -1,465,368 | -1,714,536 | -3,318,263 |
| Depreciation | 44,240 | 44,220 | 40,402 | 75,441 |
| Amortization | 50,412 | 49,857 | 49,186 | 139,022 |
| Stock-based compensation expense | 24,733 | 24,083 | 24,762 | 61,390 |
| Accounts receivable | -3,852 | -3,095 | -1,706 | -5,685 |
| Prepaid expenses and other current assets | -138,627 | -96,324 | -162,888 | -220,762 |
| Accounts payable and accrued expenses | 25,528 | -53,292 | 102,010 | -38,937 |
| Lease liability | -61,446 | -60,768 | -59,836 | -116,666 |
| Net cash used in operating activities | -1,562,212 | -1,361,849 | -1,393,418 | -2,971,566 |
| Purchases of property and equipment | 1,760 | 0 | 162,834 | 24,483 |
| Patent costs incurred | 61,936 | 78,359 | 94,985 | 58,649 |
| Net cash used in investing activities | -63,696 | -78,359 | -257,819 | -83,132 |
| Proceeds from sale of common stock, net of issuance costs | 3,693,470 | 263,068 | 116,646 | 3,423,784 |
| Payments of finance agreement | 101,171 | 67,448 | 76,691 | 230,073 |
| Net cash provided by financing activities | 3,592,299 | 195,620 | 39,955 | 3,193,711 |
| Net increase in cash | 1,966,391 | -1,244,588 | -1,611,282 | 139,013 |
| Cash - beginning of period | 5,110,630 | 6,355,218 | 7,827,487 | - |
| Cash - end of period | 7,077,021 | 5,110,630 | 6,355,218 | - |
Cardio Diagnostics Holdings, Inc. (CDIOW)
Cardio Diagnostics Holdings, Inc. (CDIOW)